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proteins of different mol. wt. (250,000 to
45,000 daltons) from the surface of trans-
formed cells.
To conclude, this is a collection of papers
of high quality, giving a very useful survey
of areas of growth in our knowledge of cell
surface structure and function. The value
of the book greatly exceeds the price
(only $5.60).
M. MOORE
Recent Topics in Chemical Carcino-
genesis. Gann Monographs on Cancer
Research, No. 17. (1975) Eds S. ODA-
SHIMA, S. TAKAYAMA and H. SATO. Balti-
more: University Park Press. pp. 456.
£27.95 net.
This monograph is dedicated to Professor
Tomizo Yoshida, and the preface includes
tributes from British, German, Japanese and
American colleagues.
The book contains many excellent papers
and the quality ofthe presentation, including
the microphotos, is of a high standard,
although unfortunately there are a number
of minor errors in the text. The topics
are grouped under four headings: Muta-
genicity and in vitro carcinogenesis; Chemis-
try and metabolism ofN-nitroso compounds;
Environmental carcinogenesis, and Experi-
mental models oftumours in various organs.
The most comprehensive section is the
fourth, in which animal studies of tumours
of the stomach, duodenum, liver, kidney,
bladder and skin are presented, together
with papers on experimentally induced leuk-
aemias. In general, however, more care
should have been taken in grouping the
papers in the different sections. There is
an obvious mistake in which the section
on chemistry and metabolism of N-nitroso
compounds should have begun with Pro-
fessor Druckrey's paper and not included
the papers on in vitro studies. It would
also have been more appropriate to open
the first section with Dr Kuroki's review
on contributions of tissue culture to the
study of chemical carcinogenesis, to be
followed by other papers on in vitro aspects
and end this section with the studies of
mutagenicity.
On balance, this monograph would seem
an expensive investment as, although there
is a considerable amount of valuable in-
formation, the price of £27.95 is high.
A. W. CRAIG
WHO Handbookfor Standardised Cancer
Registries. (WHO Offset Publication
No. 25) (1976). Geneva: World Health
Organization. pp. 94. Price Sw. Fr. 10;
US $4.00.
Although many cancer registries were
originally set up by individual hospitals
to gather data on the outcome of treatment
in their own patients, there is much to be
gained by comparing and pooling the data
of different hospitals. For example, if this
can be done for all the hospitals serving a
given population, and if cancer patients
from this population who have not been
to hospital can also be ascertained, incidence
as well as outcome can be examined. And
if such data can be gathered in a sufficiently
standard form to allow incidence and out-
come in different populations to be compared,
points at which there is scope for improving
prevention or treatment may be identified.
An internationally representative group
of distinguished experts, which met under
World Health Organization auspices to
consider how the data of different registries
might be made easier to compare, has now
produced this Handbook, recommending
what data should be collected and how some
of these data should be coded. Two kinds
of data are distinguished:
(a) core data (sufficient to fill one 80-
column punch card) which it is
considered that every hospital-based
registry should record, including pa-
tient identification particulars; site,
type, extent, and date and method
of diagnosis of neoplasm; date of
presentation at hospital; modalities
of treatment; and follow-up data;
(b) optional data on other matters that
may be related to incidence or
outcome.
According to a correction slip enclosed
with the Handbook, the phrase " (Hospital-
Based) " should be added to the title as
printed, but it would be wrong to conclude
from this that the recommendations are
not relevant to population-based registries.
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needed for monitoring incidence, which
is all some population-based registries do,
but such registries should still consider
adopting those parts of the proposed format
that are relevant to their concerns-and
as cancer control services become more
comprehensive, integrated and population-
based, the need is growing for population-
based registries to monitor outcome as well
as incidence. Some of the Handbook's
proposals for obtaining such information
have been criticized-notably its reckoning
of survival from presentation at hospital,
rather than from first treatment as has
been usual in England-but such changes
seem a small price to pay for international
comparability, and it is therefore to be
hoped that all cancer registries will do
what they can to incorporate the Handbook's
system in their own.
I. LECK
Directory of On-going Research in Can-
cer Epidemiology. (1976) Lyon: In-
ternational Agency for Research on Cancer,
and Heidelberg: Deutsches Krebsfors-
chungszentrum. 461 pp. No charge ex-
cept for postage and packing (US $5.00).
A year ago, it was reported in this and
other journals that the International Agency
for Research on Cancer, Lyon, and the
German Cancer Research Centre, Heidelberg,
were launching a Clearance-house for On-
going Research in Cancer Epidemiology, and
asking workers in this field to submit sum-
maries of their current projects for inclusion
in an annual Directory, with the aim of
acquainting those working in overlapping
fields with one another's studies and en-
couraging them to produce their results in
comparable form.
The first product of this venture is the
1976 Directory, containing summaries of
more than 600 projects, followed by sections
in which these projects are indexed by
tumour site and type, by " term " (most
of these " terms " being possible correlates
of incidence), by methodology, and by
country of origin. There is also a list of
population-based cancer registries.
The coverage provided is inevitably
uneven (some very distinguished workers'
reports are tantalisingly brief, and more
than half the projects listed are from the
United States and the United Kingdom,
as against less than 10% from the Soviet
Union and none from mainland China)
and some epidemiologists will regret the
apparent exclusion of health services research.
But the Directory still merits an enthusiastic
welcome, and it will probably soon come
to be regarded as indispensable. Future
issues might be somewhat improved by
including the pages on which each country's
entries start in the table of contents, and
by standardizing the indexing of cancer
sites so that, for example, studies of lower
respiratory tract cancer are not dispersed
between " bronchial", "lung " and " respi-
ratory " rubrics.
I. LECK
Breast Cancer: Trends in Research and
Treatment. Ed J. C. HEUSON, W. H.
MATTEIEM andM. ROZENCWEIG (1976). New
York: Raven Press. 335 pp. $28.50 net.
Allowing for the naturally slow tempo
of developments in clinical oncology, the
management of breast cancer is progressing
through a rapid and exciting phase. This
interest centres on the use of adjuvant
therapy in the early case. Much of this
is reflected in this EORTC monograph,
which is based on a conference held in
September 1975.
Information is presented on the thinking
behind adjuvant therapy and on some
of the early results. This form of therapy
can be hormonal or cytotoxic, and can use
agents singly or in combination. The trend
seems to be towards a combination of several
cytotoxic agents with a hormone preparation
(e.g. CMF plus Tamoxifen) but it is most
important that work of this sort is carried
out in a carefully controlled study, so that
reliable results can be obtained economically.
Due attention is given to short-term and
long-term toxicity. Some promising early
results are quoted, but it is still possible
that the end result will be prolongation of
recurrence-free interval (as has been demon-
strated years ago by the use of ovarian
ablation) rather than cure.
Before chemotherapy can be incorporated
into potentially curative regimes, there must
be preliminary assessment on patients with